Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $34.75.

A number of brokerages have issued reports on DNLI. Deutsche Bank Aktiengesellschaft set a $31.00 price target on Denali Therapeutics in a research note on Friday, May 22nd. Leerink Partners cut their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. UBS Group reaffirmed a “buy” rating on shares of Denali Therapeutics in a research note on Tuesday, June 16th. Finally, Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a report on Monday, June 22nd.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently made changes to their positions in the company. Foresite Capital Management VI LLC purchased a new stake in shares of Denali Therapeutics during the 3rd quarter worth approximately $14,520,000. Capricorn Fund Managers Ltd purchased a new position in shares of Denali Therapeutics in the fourth quarter valued at $1,027,000. Holocene Advisors LP grew its holdings in shares of Denali Therapeutics by 677.8% in the third quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock valued at $45,531,000 after purchasing an additional 2,732,540 shares in the last quarter. Baillie Gifford & Co. raised its stake in Denali Therapeutics by 6.2% during the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after purchasing an additional 719,304 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. AG purchased a new stake in Denali Therapeutics during the fourth quarter valued at $1,841,000. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $26.48 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $27.30. The company has a market capitalization of $4.20 billion, a P/E ratio of -9.19 and a beta of 0.96. The firm’s 50 day simple moving average is $21.95 and its two-hundred day simple moving average is $20.44.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter in the previous year, the firm posted ($0.78) EPS. Research analysts expect that Denali Therapeutics will post -2.77 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.